I do recall Resverlogix announcing an amendment to HL's licensing agreement.
"15. Other income – licensing rights fee income:
The July 2015 License Agreement between Resverlogix and Hepalink was amended effective May 1, 2020 such that Resverlogix agreed to pay up to CAD$8.0 million of clinical development costs associated with apabetalone, including a global Phase 3 clinical trial (which Resverlogix intends to perform in any event), in China, Hong Kong, Taiwan and Macau, and if the costs incurred by Resverlogix up to December 31, 2021 total less than CAD$8 million, then Resverlogix and Hepalink shall negotiate a mutuallyagreeable timeframe regarding any difference, in principle by not later than June 30, 2022."
Koo
